NASDAQ:URGN

Urogen Pharma Stock News

Healthcare > Biotechnology

Buy URGN

*Your capital is at risk

$38.56

-1.67 (-4.15%)

At Close: Jul 10, 2026

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

08:00am, Friday, 04'th Dec 2020

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dis

UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology

08:00am, Thursday, 03'rd Dec 2020

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise

UroGen Pharma Announces November 2020 Conference Schedule

08:00am, Tuesday, 10'th Nov 2020

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic dise

UroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call Transcript

03:02pm, Monday, 09'th Nov 2020

UroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call Transcript

Recap: UroGen Pharma Q3 Earnings

08:33am, Monday, 09'th Nov 2020

Shares of UroGen Pharma (NASDAQ:URGN) were unchanged after the company reported Q3 results.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by